0000950170-24-077410.txt : 20240625
0000950170-24-077410.hdr.sgml : 20240625
20240625170502
ACCESSION NUMBER: 0000950170-24-077410
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240621
FILED AS OF DATE: 20240625
DATE AS OF CHANGE: 20240625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lister Troy
CENTRAL INDEX KEY: 0002023489
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 241069786
MAIL ADDRESS:
STREET 1: C/O VERVE THERAPEUTICS, INC.
STREET 2: 201 BROOKLINE AVENUE, SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2024-06-21
false
0001840574
Verve Therapeutics, Inc.
VERV
0002023489
Lister Troy
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
false
true
false
false
Chief Scientific Officer
false
Stock Option (right to buy)
5.29
2024-06-21
4
A
false
32000
0
A
2034-06-20
Common Stock
32000
32000
D
The option was granted on June 21, 2024. 25% of the shares underlying the option will vest on June 21, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until June 21, 2028.
/s/ Andrew Ashe, as Attorney-in-Fact for Troy Lister
2024-06-25